
P R E S S R E L E A S E

STRATEC with new DNA/RNA stabilisation technology

Birkenfeld, October 7, 2004

STRATEC Biomedical Systems AG, has concluded a licence agreement with Cyclops Genome Sciences Limited to obtain worldwide exclusive rights to a technology for the stabilisation and purification of RNA and DNA from pathogens and certain other applications.

As the infectiousness of samples represents a significant hazard, one of the crucial advantages of this unique technology is that it is expected to transform the infectious RNA viruses, e.g. in whole blood, blood plasma or tissue, into non-infectious material instantaneously at the moment of stabilisation of the RNA.

The patented technology, known as "MRT" (Modified RNA Technology), was developed by Cyclops Genome Sciences.

Having secured these exclusive rights to MRT, STRATEC is able to provide its customers with a genuine competitive edge by supplementing existing technologies.

About STRATEC Biomedical Systems AG

STRATEC Biomedical Systems AG(<http://www.stratec-biomedical.de>) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems together with their own reagents to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the trading segment Gate-M of the Stuttgart Stock Exchange and on other exchanges.

Further information can be obtained from:

STRATEC Biomedical Systems AG

Investor Relations

André Loy

Gewerbestraße 37

D-75217 Birkenfeld

Tel: +49 7082 7916-190

Fax: +49 7082 7916-999

eMail: ir@stratec-biomedical.de